Request Demo
Last update 25 Jun 2026
AMT-116(Multitude Therapeutics)
Last update 25 Jun 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD44 inhibitors(CD44 antigen inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
View All Structures (2)
Boost your research with our ADC technology data.
login
or
Related
3
Clinical Trials associated with AMT-116(Multitude Therapeutics)NCT07590531
An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivosimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06782334
Phase 1/2 Study of AMT-116 in Patients with Advanced Solid Tumors
NCT05725291
First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors
100 Clinical Results associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Translational Medicine associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Patents (Medical) associated with AMT-116(Multitude Therapeutics)
Login to view more data
100 Deals associated with AMT-116(Multitude Therapeutics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 12 Jun 2026 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 24 Apr 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 164 | (all doses) | uxxjniwpki(vpmfzuukll) = ysnapowxnv qhbzksxaiq (gkhlnqzmsj ) View more | Positive | 17 Oct 2025 | ||
(≥3 mg/kg) | uxxjniwpki(lobriqlntl) = ywlgbrvxfu tpfyuzglgt (gmeygxmwfq ) View more | ||||||
Phase 1/2 | 102 | kstbzynxuy(jrsmhnjnlt) = eamnhgzwsh xdxagzdyeg (upjkafisak ) View more | Positive | 17 Oct 2025 | |||
(EGFR wild-type NSCLC) | stphvvupsl(ehujvquqig) = pkgoqtwott obmdgvazjz (kwyhvzayky ) View more | ||||||
Phase 1 | 8 | AMT-116 3 mg/kg | wznldvynvf(wrclbmlzpn) = No DLT events were observed hbxhsutzhg (axehaozdlt ) View more | Positive | 24 May 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free